Valneva Seeks to Extend IXCHIQ® Usage Through EMA and Health Canada Applications

Saint Herblain (France), September 18, 2024 - Valneva SE VALN, a company dedicated to the innovation of vaccines for infectious diseases, has reached a pivotal point. The company has officially submitted applications for label extension to two significant regulatory agencies, the European Medicines Agency (EMA) and Health Canada. These applications aim to broaden the usage of IXCHIQ®, Valneva's much-discussed chikungunya vaccine.

Understanding IXCHIQ®'s Potential

Chikungunya, a mosquito-borne virus, poses a significant public health challenge across various parts of the globe. IXCHIQ®, Valneva’s answer to this disease, has been in the spotlight as a promising vaccine to combat the virus. With the submission of label extension applications, the company is hopeful for an affirmative nod that would allow for wider administration of IXCHIQ® and offer greater protection against this debilitating virus.

Impact on Valneva's Market Position

The development and potential label extension of IXCHIQ® are critical not just for public health but also for Valneva's market standing. As the company behind this innovative vaccine, headquartered in France, VALN seeks to fortify its niche in the realm of specialized vaccines. Expansion of IXCHIQ®’s label could signify a new chapter in Valneva’s story, potentially augmenting the company’s portfolio and investor appeal.

Valneva, Vaccine, Chikungunya